{"organizations": [], "uuid": "d7078c35adc673c18e367d1ad1ad6a0e3752ac21", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kamada-gets-feedback-from-fda-on-p/brief-kamada-gets-feedback-from-fda-on-proposed-phase-3-protocol-for-inhaled-alpha-1-antitrypsin-idUSASC09WR6", "country": "US", "domain_rank": 408, "title": "BRIEF-Kamada Gets Feedback From FDA On Proposed Phase 3 Protocol For Inhaled Alpha-1-Antitrypsin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T14:50:00.000+03:00", "replies_count": 0, "uuid": "d7078c35adc673c18e367d1ad1ad6a0e3752ac21"}, "author": "", "url": "https://www.reuters.com/article/brief-kamada-gets-feedback-from-fda-on-p/brief-kamada-gets-feedback-from-fda-on-proposed-phase-3-protocol-for-inhaled-alpha-1-antitrypsin-idUSASC09WR6", "ord_in_thread": 0, "title": "BRIEF-Kamada Gets Feedback From FDA On Proposed Phase 3 Protocol For Inhaled Alpha-1-Antitrypsin", "locations": [], "entities": {"persons": [{"name": "kamada", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "kamada ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 23, 2018 / 11:50 AM / Updated 9 minutes ago BRIEF-Kamada Gets Feedback From FDA On Proposed Phase 3 Protocol For Inhaled Alpha-1-Antitrypsin Reuters Staff 2 Min Read \nApril 23 (Reuters) - Kamada Ltd: \n* KAMADA RECEIVED FEEDBACK FROM FDA ON PROPOSED PHASE 3 PROTOCOL FOR INHALED ALPHA-1-ANTITRYPSIN FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE \n* KAMADA LTD - WILL NOT BE ABLE TO INITIATE PHASE 3 CLINICAL STUDY OF INHALED AAT FOR TREATMENT OF AATD IN H2 2018 UNTIL IND IS APPROVED \n* KAMADA LTD - CANNOT CURRENTLY ANTICIPATE IF AND WHEN DISCUSSIONS WITH FDA WILL MATERIALIZE INTO AN APPROVED IND \n* KAMADA LTD - HAS FORMALLY REQUESTED, EXPECTING TO PRESENT PLANNED PHASE 3 PROTOCOL IN SCIENTIFIC ADVICE MEETING WITH EMA IN Q3 2018 \n* KAMADA - INTENDS TO PROVIDE INFORMATION REQUESTED BY FDA AND DATA, AS WELL AS IMPLEMENT PROPOSED CHANGES IN STUDY PROTOCOL, DURING Q3 2018 \n* KAMADA LTD - ANTICIPATES THAT PLANNED RESPONSE WILL RESULT IN CONTINUED INTERACTION WITH FDA \n* KAMADA - IN APRIL, FDA ISSUED RESPONSE LETTER PROVIDING FURTHER GUIDANCE, ADDITIONAL QUESTIONS REGARDING PROPOSED PIVOTAL PHASE 3 PROTOCOL, \n* KAMADA - PROPOSED MODIFICATIONS, ADDITIONAL INFORMATION TO BE PROVIDED, INTENDED TO MITIGATE CONTINUED SAFETY-RELATED CONCERNS COMMUNICATED BY FDA \n* KAMADA LTD - CORRESPONDENCE INDICATED FDA HAS CONTINUED CONCERNS AND QUESTIONS RELATED TO SAFETY PROFILE OF INHALED AAT Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-23T14:50:00.000+03:00", "crawled": "2018-04-23T15:04:53.015+03:00", "highlightTitle": ""}